Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis.
Department of Medicine, University of Toronto, Toronto, Canada. raphael.schneider@utoronto.ca
Raphael
R
Schneider
Nathalie
N
Arbour
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D001921:Brain / Q000187:drug effects / Q000473:pathology*; D003287:Contrast Media; D018592:Cross-Over Studies; D000077561:Daclizumab; D004334:Drug Administration Schedule; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D007278:Injections, Spinal; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000378:metabolism; D008279:Magnetic Resonance Imaging / Q000379:methods; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018401:Sample Size; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016176:T-Lymphocyte Subsets; D013997:Time Factors; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D003287:Contrast Media; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab